The firm said at the JP Morgan Healthcare Conference that it wants zorevunersen to be approved as a disease-modifying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback